GTA182

About GT Apeiron

Apeiron Therapeutics is a clinical-stage biotech company at the intersection of artificial intelligence and oncology drug discovery. Its core strategy involves using an AI-driven, structure-based design platform to develop targeted small molecule therapies for cancers with high unmet need, as evidenced by its lead program GTA182 already in Phase 1 trials. The company benefits from a leadership team with deep expertise in drug discovery, immuno-oncology, and cross-border biotech operations between the U.S. and China. Apeiron's approach aims to accelerate the identification and development of precision oncology drugs.

Therapeutic Areas